The Team
Executive and Board

Robert Feldman
Dr Weir has 30 years R&D and commercial experience. She successfully commercialised Phloe, the No. 1 digestive health product in New Zealand, with a successful exit to Mundipharma and Nestle. She was also Executive Director and CSO for successfully exited BioDiscovery NZ, and was integral in this company’s license agreements with Monsanto and Syngenta. Iona also served as Executive Director for both Lypanosys (Eczema oral pharmaceutical) and Meracol Corporation (IBSacol), with general management and R&D responsibilities for both companies. She has held several other executive directorships, CEO and CSO roles. Iona has also developed, commercialised and is in process of a multinational license agreement (pending COVID-19 outcome) on NZ native edible fungi for Asian markets. As Executive Director of Tawhiwhi Bioactives Iona has developed a kiwifruit medical food drink which is currently in scale up with an international party for the US market. Has also undertaken numerous consulting projects for US-based companies on Botanical drug, Medical Foods and OTC R&D and regulatory strategies.

The foundations of Iona’s research expertise were the first twelve years of career, spent in the government sector as a Senior Scientist and Bioactives Team Leader. She was awarded an international award for outstanding PhD proving that apoptosis occurs in plants, Young Scientist award for research showing that plant supplements alter chemotherapy success rates, and the top Marsden research grant. Iona also led commercially successful projects with Beckman Coulter, Zespri, Comvita, Living Nature, Frucor, Healtheries and Arborgen. She has also completed a sabbatical at the Ontario Cancer Institute/University of Toronto as well as research project stints at Cambridge University, CNRS (Paris), University of Arizona, Los Alamos Research Centre, Australian National University and Queensland Institute of Medical Research.


Board

Paul Dallimore
Paul is an experienced director with expertise in corporate governance, investment analysis, investor communication and project delivery. He was the founder and Executive Chairman of the NZX listed National property Trust, which commenced as a $20 million property investment vehicle and became a $270 million NZX listed entity with retail and commercial properties throughout the country. The properties were acquired via takeovers and mergers of other property vehicles. Largest transaction was the takeover of the Newmarket Property Trust for $80 million and another notable takeover was the Southway Property Group- owners of Eastgate and Hornby shopping malls in CHCH for $50 million.

Paul is Chairman and owner of the Highgate Group of companies with interest in land development, retail & commercial property and private equity investments. He is also Project Director and shareholder for a private investment company currently undertaking in excess of $150 million of project work. Paul was awarded a Companion to the Queens Service Order (QSO) in 2010 for service to arts philanthropy and is a Fellow of the New Zealand Institute of Management (FNZM), the Australasian Institute of Managers and Leaders (FIML) and a member of the Institute of Directors (MinstD)
Robert Feldman
Robert has an invaluable combination of business, medical and research experience spanning over two decades. A qualified medical practitioner, he obtained his medical degree in London, his PhD in the Netherlands, has worked at Harvard Medical School and held clinical and academic positions at Imperial College, London. Robert is a successful serial life science entrepreneur, having founded the UK vaccine company Microscience and antimicrobial company Vmax. He later went on to become CEO of hepatitis C therapeutic company, RioTech before establishing the European operations for the New York based company Paramount Biosciences, LLC. As Entrepreneur in Residence for Imperial Innovations, London, Robert also co-founded the spin-out company, Indigix. In 2010, he moved to New Zealand as Executive Director of Pacific Channel and subsequently founded his own life science consulting company, Line 5.

During his extensive and varied career, Robert has developed a breadth of medical and research expertise encompassing therapeutics, devices, diagnostics and functional preparations in the field of human health. He has also gained a deep understanding of business and product development, fundraising, venture and governance. In addition to Dr Feldman’s work in the UK and New Zealand, he has also engaged in business development activities in several other countries, including successful licensing deals in Europe, USA, Australia, Russia, South Korea and New Zealand.

He supports both early-stage and mature life science businesses. He actively performs due diligence for investors and engages in company troubleshooting, commercialising opportunities, strategic and business planning, business and product development, and operations. Alongside his work with Decima Health, Life Science New Zealand and Line 5, Robert is a non-executive director of Canterbury Scientific Ltd, chair of its Scientific Advisory Panel and head of the company’s CS Ventures initiative.